Table 2.
Comparison of clinical, biochemical, and hormonal parameters of PCOS patients and the control group based on the TPOAbs status.
| Control group | PCOS | P | |||
|---|---|---|---|---|---|
| TPOAbs negative (n = 67) | TPOAbs positive (n = 21) | TPOAbs negative (n = 110) | TPOAbs positive (n = 31) | ||
| Age (years) |
25 (22–27) |
27 (24–29) |
24 (22–27) |
25.5 (23–30) |
0.01 post-hoc all p > 0.05 |
| BMI (kg/m2) |
21.8 (20.6–23.4) |
22.5 (20.9–24.7) |
23.4 (21.4–26.3)a |
25 (22.2–29)c |
<0.01 post-hoc all p < 0.01 |
| WC (cm) |
77 (73–82) |
77.5 (69.5–83) |
80 (74–93) |
87 (77–97)c,d |
<0.01 post-hoc all p ≤ 0.01 |
| FSH (IU/l) |
5.4 (4.4–6.5) |
5.5 (4.4–6.7) |
4.8 (3.8–6.0) |
5.2 (4.2–6.0) |
0.15 |
| LH (IU/l) |
4.0 (2.9–5.0) |
4.0 (3.2–5.0) |
3.9 (3.1–5.1) |
5.3 (3.5–7.0)c |
0.03 post-hoc p = 0.03 |
| TT (ng/ml) |
0.52 (0.4–0.68) |
0.53 (0.38–0.63) |
0.7 (0.58–0.88)a,b |
0.79 (0.64–1.0)c,d |
<0.01 post-hoc all p < 0.01 |
| SHBG (nmol/l) |
63 (46–88) |
73 (59–91) |
47 (30–61)a,b |
44 (25–56)c,d |
<0.01 post-hoc all p < 0.01 |
| FAI | 2.8 (2.0–3.7) |
2.0 (1.5–3.0) |
5.3 (3.2–8.0)a,b |
6.4 (4.3–11.2)c,d |
<0.01 post-hoc all p < 0.01 |
| Estradiol (pg/ml) |
53 (28–71) |
67 (56–90) |
55 (38–74) |
61 (47–81) |
0.10 |
| PRL (ng/ml) |
11.8 (7.9–22.8) |
9.1 (5.5–10.3) |
13.2 (8.0–22.2) |
10.2 (8–17.5) |
0.05 |
| TSH (uIU/ml) |
1.7 (1.2–2.4) |
1.8 (1.5–2.8) |
1.9 (1.3–2.5) |
1.8 (1.1–3.3) |
0.55 |
| fT4 (ng/dl) |
1.2 (1.1–1.3) |
1.3 (1.2–1.4) |
1.3 (1.2–1.4) |
1.2 (1.1–1.3) |
0.06 |
| fT3 (pg/ml) |
3.1 (2.7–3.6) |
3.3 (2.4–3.7) |
3.5 (3.1–3.8)a |
3.5 (2.9–3.8) |
0.03 post-hoc p=0.04 |
| Glucose 0′ OGTT (mg/dl) |
91 (87–96) |
93 (88–96) |
92 (89–98) |
89 (85–97) |
0.42 |
| Glucose 120′ OGTT (mg/dl) |
93 (78–101) |
90 (75–99) |
95 (83–105) |
93 (78–125) |
0.43 |
| Insulin 0′ OGTT (uIU/ml) |
8.3 (6.8–11.1) |
7.7 (7.3–10.2) |
10 (7.6–14) |
10.2 (7.1–14.4) |
0.03 post-hoc all p > 0.05 |
| Insulin 120′ OGTT (uIU/ml) |
31.8 (21.2–47.2) |
25.4 (18.8–31.8) |
38.2 (24.8–60.7)b |
30.4 (18.1–62.9) |
0.02 post-hoc p = 0.04 |
| HOMA-IR | 1.8 (1.5–2.5) |
1.8 (1.6–2.4) |
2.1 (1.6–3.2) |
2.3 (1.4–3.7) |
0.25 |
| Total cholesterol (mg/dl) |
170 (153–191) |
180 (148–195) |
173 (160–194) |
175 (157–198) |
0.57 |
| HDL-cholesterol (mg/dl) |
65 (58–79) |
70 (60–78) |
68 (54–77) |
59 (50–74) |
0.30 |
| LDL-cholesterol (mg/dl) |
87 (71–105) |
94 (80–100) |
91 (78–108) |
91 (79–113) |
0.43 |
| TG (mg/dl) |
58 (42–77) |
49 (44–63) |
65 (52–92)a |
68 (52–106)c,d |
<0.01 post-hoc all p < 0.05 |
| AMH (ng/ml) |
5.3 (3.4–8.6) |
5.1 (2.8–9.8) |
8.6 (5.9–12.2)a,b |
8.3 (4.8–13.2)c |
<0.01 post-hoc all p ≤ 0.04 |
| OV (cm3) |
11 (7.8–13.7) |
10.4 (7.5–12.8) |
14.3 (10.6–20.2)a,b |
15.5 (10.9–18.6)c,d |
<0.01 post-hoc all p < 0.01 |
| TV (ml) |
9.6 (7.9–12.3) |
11.4 (8.7–14.9) |
10 (8.3–12.8) |
10.5 (8.8–13.6) |
0.47 |
Values are expressed as median (interquartile range).
p < 0.05 PCOS with negative TPOAbs vs. control with negative TPOAbs.
p < 0.05 PCOS with negative TPOAbs vs. control with positive TPOAbs.
p < 0.05 PCOS with positive TPOAbs vs. control with negative TPOAbs.
p < 0.05 PCOS with positive TPOAbs vs. control with positive TPOAbs.
BMI, body mass index; WC, waist circumference; TT, total testosterone; TG, triglycerides; OGTT, oral glucose tolerance test; FSH, follicle-stimulating hormone; LH, luteinizing hormone; FAI, free androgen index; SHBG, sex hormone binding globulin; HOMA-IR, homeostasis model assessment of insulin resistance; TSH, thyroid-stimulating hormone; fT4, free T4; fT3, free T3; AMH, anti-Müllerian hormone; OV, ovarian volume; TV, thyroid volume.